Chufang Li
Overview
Explore the profile of Chufang Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
860
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dong J, Dong Z, Feng P, Gao Y, Li J, Wang Y, et al.
Vaccines (Basel)
. 2023 Feb;
11(2).
PMID: 36851268
Live attenuated influenza vaccines offer broader and longer-lasting protection in comparison to inactivated influenza vaccines. The neuraminidase (NA) surface glycoprotein of influenza A virus is essential for the release and...
2.
Wu X, Jie F, Li P, Zhuo C, Pan W, Zhong N, et al.
J Thorac Dis
. 2023 Feb;
15(1):22-32.
PMID: 36794141
Background: Influenza virus infection complicated by secondary bacterial pneumonia contributes significantly to death during seasonal or pandemic influenza. Secondary infection of () in influenza virus-infected patients contributes to morbidity and...
3.
Jie F, Wu X, Zhang F, Li J, Liu Z, He Y, et al.
Microbiol Spectr
. 2022 Dec;
11(1):e0365522.
PMID: 36475755
No abstract available.
4.
Peng J, Ran Y, Xie H, Deng L, Li C, Ling C
J Virol
. 2021 Mar;
95(10).
PMID: 33692207
Influenza A virus is an important human pathogen causing significant morbidity and mortality. Numerous host factors and cellular responses are dysregulated during influenza A virus infection. This includes arrest of...
5.
Luo S, Guo L, Sheng C, Zhao Y, Chen L, Li C, et al.
Acta Pharm Sin B
. 2020 Nov;
10(10):1846-1855.
PMID: 33163339
Neuraminidase inhibitors (NAIs) are the mainstay antiviral drugs against influenza infection. In this study, a ligand fishing protocol was developed to screen NAIs using neuraminidase immobilized magnetic beads (NA-MB). After...
6.
Ma Q, Li R, Pan W, Huang W, Liu B, Xie Y, et al.
Phytomedicine
. 2020 Sep;
78:153296.
PMID: 32890913
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has extensively and rapidly spread in the world, causing an outbreak of acute infectious pneumonia. However, no specific antiviral drugs or vaccines...
7.
Feng L, Wang Q, Shan C, Yang C, Feng Y, Wu J, et al.
Nat Commun
. 2020 Aug;
11(1):4207.
PMID: 32826924
The rapid spread of coronavirus SARS-CoV-2 greatly threatens global public health but no prophylactic vaccine is available. Here, we report the generation of a replication-incompetent recombinant serotype 5 adenovirus, Ad5-S-nb2,...
8.
Wang Y, Lv Y, Niu X, Dong J, Feng P, Li Q, et al.
J Virol
. 2020 Aug;
94(20).
PMID: 32796071
Since the first outbreak in 2013, the influenza A (H7N9) virus has continued emerging and has caused over five epidemic waves. Suspected antigenic changes of the H7N9 virus based on...
9.
Ma Q, Pan W, Li R, Liu B, Li C, Xie Y, et al.
Pharmacol Res
. 2020 May;
158:104850.
PMID: 32360580
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide through person-to-person contact, causing a public health emergency of international concern. At present, there is no specific antiviral treatment recommended...
10.
Dong J, Chen P, Wang Y, Lv Y, Xiao J, Li Q, et al.
Antiviral Res
. 2020 Mar;
177:104776.
PMID: 32201204
Highly pathogenic influenza H7N9 viruses that emerged in the fifth wave of H7N9 outbreak pose a risk to human health. The World Health Organization has updated the candidate vaccine viruses...